Miscellaneous Drugs
Last Updated: October 10, 2023
Summary Recommendations | Summary Recommendations |
|---|
Fluvoxamine- There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.
Intravenous Immunoglobulin- The Panel recommends against the use of intravenous immunoglobulin (IVIG) for the treatment of acute COVID-19 in adults and children, except in a clinical trial (AIII). This recommendation should not preclude the use of IVIG when it is otherwise indicated for the treatment of underlying conditions or complications that arise during the course of COVID-19.
- For the Panel’s recommendations on the use of IVIG in children with multisystem inflammatory syndrome in children (MIS-C), see Therapeutic Management of Hospitalized Children With MIS-C, Plus a Discussion on MIS-A.
Ivermectin- The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
Metformin- There is insufficient evidence for the Panel to recommend either for or against the use of metformin for the treatment of COVID-19 in nonhospitalized patients.
- The Panel recommends against the use of metformin for the treatment of COVID-19 in hospitalized patients, except in a clinical trial (BIII).
- Patients with COVID-19 who are receiving metformin for an underlying condition should continue this therapy as directed by their health care provider (AIII).
The section on Colchicine has been archived. The Panel will no longer be updating the information on that therapy. |
| Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information. |
